Daprodustat manufacturers and global supply

Daprodustat (Daprodustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mainly used to treat chronic kidney disease (CKD)-related anemia. Its R&D and production are handled by multinational pharmaceutical companies. The original drug has not yet been launched in the domestic market, so domestic patients mainly learn about its use through overseas channels. The purpose of the research and development of daprostat is to provide a new oral anemia treatment option for long-term dialysis and non-dialysis CKD patients. Compared with traditional injectable erythropoietin drugs, daprostat is convenient to take and has high compliance. It also has a stable improvement effect on iron metabolism and hemoglobin levels.

Globally, the original drug of daprostat is mainly supplied by original manufacturers in the European, American and Japanese markets. Common overseas specifications are1 mg 30 tablets, 2 mg 30 tablets, etc., to meet the dose adjustment of different patients' weight and hemoglobin needs. Overseas marketing experience shows that the drug has good long-term use effects among dialysis patients and has high hemoglobin stability. At the same time, the oral administration reduces the occurrence of injection-related adverse reactions, making daily management of patients more convenient.

In addition to the original drug, the first generic version of daprostat has appeared in some overseas regions, which provides greater potential for drug accessibility. For example, the specification of generic drugs produced by Lucius Pharmaceuticals in Laos is 1mg*100 tablets, and the ingredients of the drugs are basically the same as those of the original drugs. The emergence of this type of generic drugs helps reduce treatment costs and provides new options for patients with limited financial conditions. It also promotes the popularity of HIF-PHI drugs in the treatment of anemia in chronic kidney disease around the world.

It is worth noting that the global supply of daprostat still relies on a complete logistics and drug management system. The production of original drugs and generic drugs must strictly followGMP standards to ensure drug quality and patient safety.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat